Christopher Lindop Insider Profile
4 Followers
Christopher Lindop, CFO & EVP Business Development at Haemonetics, holds 376.65K shares in Quotient (Ticker: QTNTQ), holds 20.25K shares in Parexel (Ticker: PRXL), holds 56.74K shares in Haemonetics (Ticker: HAE).
Christopher Lindop's Trading History
| QTNTQQuotient | Oct 30, 2017 | ― | Uninformative Buy | 243.44K | $14.69K | |
| PRXLParexel | Oct 04, 2017 | ― | Uninformative Sell | ― | $1.78M | |
| HAEHaemonetics | Jan 19, 2016 | CFO & EVP Business Development | Uninformative Buy | 113.93 | $6.81M | |
| ~ALRAlere Inc | ― | ― | ― | $0.00 |
You May Also Like
Christopher Lindop insider profile FAQ
What is the percentage of profitable transactions made by Christopher Lindop?
The percentage of profitable transactions made by Christopher Lindop is 40%.
What is the average return per transaction made by Christopher Lindop?
The average return per transaction made by Christopher Lindop is -9.60%.
What stocks does Christopher Lindop hold?
Christopher Lindop holds: HAE, QTNTQ, PRXL, ~ALR stocks.
What was Christopher Lindop’s latest transaction?
Christopher Lindop’s latest transaction was an Uninformative Buy of $243.44K.
What was Christopher Lindop's most profitable transaction?
Christopher Lindop’s most profitable transaction was an Informative Sell of PRXL stock on February 19, 2015. The return on the trade was 8.40%.
What is Christopher Lindop's role in Haemonetics?
Christopher Lindop's role in Haemonetics is CFO & EVP Business Development.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
